Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RECOVERY
NCT04381936Phase 3Recruiting
- Sponsor
- University of Oxford
- Start
- Mar 2020
- Primary completion
- Sep 2028
- Modality
- Antibody Conjugates, Monoclonal Antibodies, Orthosteric Ligands
- Countries
- 16
01
Overview
Phase 3, randomised, open-label trial of lopinavir + ritonavir, dexamethasone, hydroxychloroquine, azithromycin, convalescent plasma (Heinrich-Heine University, Duesseldorf) and 14 more in pneumonia, coronavirus disease 2019 (COVID-19) and influenza (23 arms), sponsored by University of Oxford. Primary endpoints: All-cause mortality at 28 days and Time to discharge alive from hospital at 28 days. Started Mar 2020; status: recruiting.
02
Drugs
lopinavir + ritonavirdexamethasonehydroxychloroquineazithromycinconvalescent plasma (Heinrich-Heine University, Duesseldorf)
03
Conditions
pneumoniacoronavirus disease 2019 (COVID-19)influenza
Beyond the preview
Go deeper on NCT04381936.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04381936.